Development of a prediction model for the acquisition of extended spectrum beta-lactam-resistant organisms in U.S. international travellers
Year: 2023
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Extended spectrum beta-lactamase producing Enterobacterales (ESBL-PE) present a risk to public health by limiting the efficacy of multiple classes of beta-lactam antibiotics against infection. International travellers may acquire these organisms and identifying individuals at high risk of acquisition could help inform clinical treatment or prevention strategies. METHODS: We used data collected from a cohort of 528 international travellers enrolled in a multicentre US-based study to derive a clinical prediction rule (CPR) to identify travellers who developed ESBL-PE colonization, defined as those with new ESBL positivity in stool upon return to the United States. To select candidate features, we used data collected from pre-travel and post-travel questionnaires, alongside destination-specific data from external sources. We utilized LASSO regression for feature selection, followed by random forest or logistic regression modelling, to derive a CPR for ESBL acquisition. RESULTS: A CPR using machine learning and logistic regression on 10 features has an internally cross-validated area under the receiver operating characteristic curve (cvAUC) of 0.70 (95% confidence interval 0.69-0.71). We also demonstrate that a four-feature model performs similarly to the 10-feature model, with a cvAUC of 0.68 (95% confidence interval 0.67-0.69). This model uses traveller's diarrhoea, and antibiotics as treatment, destination country waste management rankings and destination regional probabilities as predictors. CONCLUSIONS: We demonstrate that by integrating traveller characteristics with destination-specific data, we could derive a CPR to identify those at highest risk of acquiring ESBL-PE during international travel.
Source: Journal of Travel Medicine
DOI: 10.1093/jtm/taad028
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,217
Funders: U.S. Department of Health and Human Services, National Institutes of Health, Centers for Disease Control and Prevention, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Advancing genomic, transcriptomic and functional approaches to combat globally important and emerging pathogens, G2898696312, GLOBAL TRAVEPINET (GTEN): U.S. TRAVELERS? HEALTH RESEARCH, SURVEILLANCE, COMMUNICATION AND OUTREACH NETWORK, GLOBAL TRAVEPINET (GTEN): THE HEADING HOME HEALTHY PROGRAM AND GLOBAL TRAVELERS' HEALTH NATIONAL RESEARCH CENTER CONSORTIUM, GUIDANCE AND OUTREACH PR, Utah Center for Clinical and Translational Science, G8014130074, Training Program in Genomic Medicine, Single dose azithromycin to prevent cholera in children, Development of clinical decision tools for management of diarrhea of children in high and low resource settings
OpenAlex ID: W4323037587
